Study provides evidence that restoring miR223-3p before cells convert to cancer can even prevent BRCA1-related disease.

‘MiR223-3p acts like a light switch, turning off proteins that BRCA1-mutant cancers need to divide properly. Without these key cell division proteins, BRCA1-mutant tumors commit suicide. ’

A tiny molecule called microRNA (miR) 223-3p prevents normal cells from making mistakes while repairing their DNA. However, cancers with BRCA1 mutations repress miR223-3p to permit their cells to divide. Adding back miR223-3p forces the BRCA1-mutant cancer cells to die, said study co-author Patrick Sung, D. Phil. Dr. Sung, who joined UT Health San Antonio in 2019 from Yale, is a BRCA1 cancer expert who occupies the Robert A. Welch Distinguished Chair in Biochemistry. 




Exploiting the cancer's Achilles' heel
"It's kind of a cool way of thinking about treatment," Dr. Hromas said. "We are using the very nature of these BRCA1-deficient cancer cells against them. We are attacking the very mechanism by which they became a cancer in the first place."
BRCA gene mutations affect 1 in every 400 people in the United States -- an estimated 825,000. After Ashkenazi Jews, Hispanics have the second-highest prevalence of BRCA1 disease-causing mutations. The disease's burden in San Antonio and South Texas is therefore among the highest in the country.
Source-Eurekalert